Liver biopsy technique in the era of genomic cancer therapies: a single-center retrospective analysis

Ozeki, Yusuke; Kanogawa, Naoya; Ogasawara, Sadahisa; Ogawa, Keita; Ishino, Takamasa; Nakagawa, Miyuki; Fujiwara, Kisako; Unozawa, Hidemi; Iwanaga, T.; Sakuma, Takafumi; Fujita, Naoto; Kojima, Ryuta; Kanzaki, Hiroaki; Koroki, Keisuke; Kobayashi, Kazufumi; Nakamura, Masato; Kiyono, Soichiro; Kondo, Takayuki; Saito, Tomoko; Nakagawa, Ryo; Suzuki, Eiichiro; Ooka, Yoshihiko; Nakamoto, Shingo; Muroyama, Ryosuke; Tawada, Akinobu; Chiba, Tetsuhiro; Arai, Makoto; Kato, Jun; Ikeda, Jun‐ichiro; Takiguchi, Yuichi; Kato, Naoya

doi:10.1007/s10147-022-02195-9

Cited by 3 publications

(3 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 At the same time, the liver puncture technique can be used as an ideal treatment for liver tumours, and some malignant liver tumours can be treated by interventional therapy through liver puncture. 29 Therefore, liver puncture plays an irreplaceable role in the diagnosis and treatment of liver malignant tumours.…”

Section: Discussionmentioning

confidence: 99%

The Diagnostic Value of Liver Biopsy for Unexplained Liver Dysfunction: A Retrospective Study

Shi,

Yang,

et al. 2024

JMDH

View full text Add to dashboard Cite

To analyse clinical manifestations of unexplained abnormal liver function and perform hepatobiliary histopathology procedures on patients to evaluate the value of liver biopsy in diagnosing the aetiology of unexplained abnormal liver function. Methods: A convenience sampling method was used to retrospectively collect the data of patients who were diagnosed with unexplained abnormal liver function and who received liver biopsy in the Pathology Department of Tianjin Second People's Hospital, China, between March 2022 and July 2023 to analyse liver pathology and clinical manifestations. Results: A total of 1302 patients were included in this study, which mainly included 11 diseases: autoimmune liver disease (74 cases, 5.68%), drug-induced liver injury (DILI) (204 cases, 15.67%), cancer (237 cases, 18.20%), non-alcoholic fatty liver disease (104 cases, 7.99%), non-alcoholic steatohepatitis (74 cases, 5.68%), viral hepatitis (490 cases, 37.63%), other types of hepatitis (30 cases, 2.30%), cholestatic liver disease (17 cases, 1.31%), alcoholic liver disease (15 cases, 1.15%), hepatic cyst (5 cases, 0.38%) and Gilbert syndrome (4 cases, 0.31%). The success rate of liver biopsy sampling was 100%, and (1.52 ± 0.130) tissue strips were sampled. The average operating time was 11.52 minutes. The percutaneous liver biopsy did not significantly increase short-term liver function index values (serum γ-glutamyl transpeptidase, total bilirubin, alanine transaminase, aspartate aminotransferase, alkaline phosphatase). Ninety-two patients had a small amount of liver subcapsular fluid, but there was no progress after medical treatment. Conclusion: Ultrasound-guided percutaneous liver biopsy has value in the diagnosis of unexplained abnormal liver function. Viral hepatitis, cancer and DILI are the most common causes of unexplained abnormal liver function. Liver biopsy does not aggravate the organic and functional impairment of the liver.

show abstract

Section: Discussionmentioning

confidence: 99%

The Diagnostic Value of Liver Biopsy for Unexplained Liver Dysfunction: A Retrospective Study

Shi,

Yang,

et al. 2024

JMDH

View full text Add to dashboard Cite

show abstract

Section: Genomic Analysis Of Liver Cancers Using Eus-fna/fnb Specimensmentioning

confidence: 99%

“…Several studies have reported that percutaneous liver biopsy can be performed for CGP analysis in primary or metastatic liver cancers [ 75 , 118 ]. Eso et al [ 75 ] and Ozeki et al [ 118 ] reported that the success rate of CGP analysis was 100% (22/22) and 84.9% (62/73), respectively. Moreover, several studies have been reported on sequencing analysis of liver cancers using EUS-FNA/FNB specimens (Table 4 ) [ 101 , 103 ].…”

Section: Genomic Analysis Of Liver Cancers Using Eus-fna/fnb Specimensmentioning

confidence: 99%

Current status and issues in genomic analysis using EUS-FNA/FNB specimens in hepatobiliary–pancreatic cancers

Ozono,

Kawakami,

Uchiyama

et al. 2023

J Gastroenterol

View full text Add to dashboard Cite

Comprehensive genomic profiling based on next-generation sequencing has recently been used to provide precision medicine for various advanced cancers. Endoscopic ultrasound (EUS)-guided fine-needle aspiration (EUS-FNA) and EUS-guided fine-needle biopsy (EUS-FNB) play essential roles in the diagnosis of abdominal masses, mainly pancreatic cancers. In recent years, CGP analysis using EUS-FNA/FNB specimens for hepatobiliary–pancreatic cancers has increased; however, the success rate of CGP analysis is not clinically satisfactory, and many issues need to be resolved to improve the success rate of CGP analysis. In this article, we review the transition from EUS-FNA to FNB, compare each test, and discuss the current status and issues in genomic analysis of hepatobiliary–pancreatic cancers using EUS-FNA/FNB specimens.

show abstract

Heterogeneous Pathological Changes in Liver Lobes During Liver Disease: A Perspective Review

Bernardo,

Godoy,

Eik Filho

et al. 2024

Metabolic Syndrome and Related Disorders

View full text Add to dashboard Cite

Liver biopsy technique in the era of genomic cancer therapies: a single-center retrospective analysis

Cited by 3 publications

References 50 publications

The Diagnostic Value of Liver Biopsy for Unexplained Liver Dysfunction: A Retrospective Study

The Diagnostic Value of Liver Biopsy for Unexplained Liver Dysfunction: A Retrospective Study

Current status and issues in genomic analysis using EUS-FNA/FNB specimens in hepatobiliary–pancreatic cancers

Heterogeneous Pathological Changes in Liver Lobes During Liver Disease: A Perspective Review

Contact Info

Product

Resources

About